Stenzl - Figure 3
Should molecular profiling of bladder tumors be done, and what are the consequences?
FIG. 3: The question we are tackling in this presentation concerns the problem of having molecular profiling at the time of an initial transurethral resection of the bladder (TURB).
- Can molecular profiling of T1 tumors be the main driver for a therapeutic strategy?
- Which tumors would be suitable for neoadjuvant therapy?
- Which systemic therapy should we apply first, especially with some new drugs becoming available?
- How do we monitor systemic therapy in metastatic urothelial cancer in order to know how many and what type of systemic therapy cycles we should apply?
